HomeCompareFPHHF vs JNJ

FPHHF vs JNJ: Dividend Comparison 2026

FPHHF yields 2.76% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $6.3K in total portfolio value· pulled ahead in Year 8
10 years
FPHHF
FPHHF
● Live price
2.76%
Share price
$1.39
Annual div
$0.04
5Y div CAGR
0.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.0K
Annual income
$356.27
Full FPHHF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — FPHHF vs JNJ

📍 JNJ pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFPHHFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FPHHF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FPHHF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FPHHF
Annual income on $10K today (after 15% tax)
$234.96/yr
After 10yr DRIP, annual income (after tax)
$302.83/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,683.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FPHHF + JNJ for your $10,000?

FPHHF: 50%JNJ: 50%
100% JNJ50/50100% FPHHF
Portfolio after 10yr
$27.1K
Annual income
$2,522.84/yr
Blended yield
9.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

FPHHF
No analyst data
Altman Z
1.2
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FPHHF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFPHHFJNJ
Forward yield2.76%2.13%
Annual dividend / share$0.04$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0.7%28%
Portfolio after 10y$24.0K$30.3K
Annual income after 10y$356.27$4,689.40
Total dividends collected$3.2K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FPHHF vs JNJ ($10,000, DRIP)

YearFPHHF PortfolioFPHHF Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,978$278.36$10,592$272.30+$386.00FPHHF
2$12,034$287.60$11,289$357.73+$745.00FPHHF
3$13,174$296.70$12,123$472.89+$1.1KFPHHF
4$14,401$305.67$13,141$629.86+$1.3KFPHHF
5$15,724$314.48$14,408$846.81+$1.3KFPHHF
6$17,148$323.14$16,021$1,151.60+$1.1KFPHHF
7$18,680$331.66$18,122$1,588.22+$558.00FPHHF
8← crossover$20,327$340.01$20,930$2,228.20$603.00JNJ
9$22,099$348.22$24,792$3,191.91$2.7KJNJ
10$24,002$356.27$30,274$4,689.40$6.3KJNJ

FPHHF vs JNJ: Complete Analysis 2026

FPHHFStock

First Philippine Holdings Corporation engages in the power generation, real estate development, manufacturing, and construction and others business in the Philippines. It generates power through natural gas-fired, hydroelectric, geothermal, and wind and solar power plants. The company also develops residential and commercial projects; operates cinema and hotels; develops and manages industrial estate; leases, owns, acquires, and sells real and personal properties, and land; maintains and cleans buildings and other facilities; supplies water; and provides waste management and sewage treatment facilities. In addition, it offers dry-type and fluid-immersed transformers, and electronic and electrical products; and packaged substation, project, technical services, and other power solutions. Further, the company constructs power plants, transmission lines, public infrastructure, and electro-mechanical works; provides drilling and workover services for exploratory or development geothermal wells; rents and leases trucks, tractors, vans, buses, trailers, light and heavy equipment, and other motor vehicles; produces, develops, and crushes concrete aggregates and other related products; and supplies petroleum products. Additionally, it is involved in the retail and office leasing activities; hauling, trucking, and delivery of goods and materials; quarrying and the production of rocks, stones, and other related products; provision of transport for trading and distribution, and specialized medical services; oil transporting, securities transfer, medical and research, education, financing, and other activities; and construction and operation of liquid or gas pipeline. The company was formerly known as Meralco Securities Corporation and changed its name to First Philippine Holdings Corporation in September 1972. The company was incorporated in 1961 and is based in Pasig, the Philippines. First Philippine Holdings Corporation is a subsidiary of Lopez Holdings Corporation.

Full FPHHF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this FPHHF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FPHHF vs SCHDFPHHF vs JEPIFPHHF vs OFPHHF vs KOFPHHF vs MAINFPHHF vs ABBVFPHHF vs MRKFPHHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.